About Marigold Innovation
Marigold Innovation is a partner-owned company founded in 2018 with the aim to:
-
identify academic research projects that can serve as the foundation for unique solutions to unresolved medical challenges,
-
mature these projects together with researchers toward early proof of concept,
-
establish and manage businesses based on these technologies in collaboration with researchers, with the ultimate goal to sell them to the right pharmaceutical companies.
Far too many major biotechnological inventions never progress beyond the laboratory as scientific inventors often lack the diverse expertise required to successfully establish and run a biotech company.
Together with our partners, we provide the necessary expertise to transform groundbreaking biotech inventions into solid and successful biotech companies – TOGETHER with the researchers.
We facilitate major innovation leaps, guiding projects from the laboratory to startup formation and ultimately to the sale of drug candidates to established pharmaceutical companies.
Marigold builds successful businesses from candinavia’s top biotechnology laboratories in close collaboration with researchers to bring the discoveries to market.
150
Number of screened projects
4
Number of investments
2021
First investment
Management af
Marigold Innovation
Charlotte Dyring
CEO & Partner
Jacob Ørndrup
Chairman of the Board & Partner
Peter Horn Møller
Board Member & Partner
Benny Buchardt Andersen
Board Member & Partner
Researchers and investors
Researchers and investors operate in two different worlds. For scientific discoveries to be successfully translated into businesses, these worlds must be connected, which is often challenging. This disconnect is why many great scientific ideas often remain unrealized. It is not due to a lack of scientific progress or commercial potential but rather that very few researchers possess the full range of skilles needed to bring their discoveries to a commercial level. The combination of necessary competencies simply becomes too overwhelming.
An academic scientific career requires sharp specialization and a focused approach within a relatively narrow field. While this focus is essential for groundbreaking research, it leaves little time and capacity for the researcher to manage the many other critical aspects needed to mature a biotech company. In addition, researchers and investors operate in two different worlds.
Through a partnership with Marigold Innovation we bridge this gap by managing everything, that the researchers do not master letting the skilled researchers focus on what they do best – research. In addition, we know how to connect science and investments, to ensure that scientific discoveries are successfully translated into businesses. To the benefit of the society, the patients, the researchers, and the investors.
Why our approach works:
-
We engage directly with researchers in the laboratory and ease their burden by taking responsibility for the commercial aspects, allowing them to focus on advancing the science.
-
We refine the technology towards proof-of-concept data in a relevant model – preferably an animal model – and develop the business plan before co-founding a company with the researchers.
-
We close the gap between academic research and industry by providing the necessary expertise and capital, creating a professional business.
-
Our model ensures a seamless transition from research to the establishment of a commercial enterprise, which can ultimately be sold to the right pharmaceutical company.
What We Offer:
-
Capital: We provide funding for promising biotech projects and ensure the necessary resources to progress through the development phases.
-
Professional co-founder: As a committed partner and co-founder, we offer strategic guideance and hands-on execution in areas such as business development, drug development planning, IP strategy, legal expertise, financing strategy, and team building.
-
Targeted towards the pharma market: Our goal is to advance biotech projects to a stage where they become attractive to the pharmaceutical industry and ready for a successful transition.
The partner group behind Marigold Innovation
Charlotte Dyring
CEO & Partner
Background: Charlotte holds an MSc in chemical engineering and a PhD in Biotechnology.
Charlotte has over 30 years of experience in the pharmaceutical and biotech industries, having held positions as both researcher and leader. As co-founder and former CEO of ExpreS2ion Biotechnologies, she led the company through a successful IPO on Nasdaq First North in 2016. She has also built partnerships with pharmaceutical companies and world-renowned universities.
Jacob Ørndrup
Chairman of the Board & Partner
Background: Jacob is a lawyer with more than 25 years of experience in the biotech sector.
Jacob is a Partner at Loeven Law Firm. He has advised a very wide range of clients within biotech, pharma and medtech, ranging from Big Pharma to biotech start-ups and founders. His expertise covers in particular IP, licensing, contract negotiation, and regulatory law.
Peter Horn Møller
Board Member & Partner
Background: Peter holds a master’s degree in biochemistry and organic chemistry, as well as a PhD in medical science.
Peter has over 25 years of experience in IP strategy and licensing and a strong track record of translating advanced research into commercial products. He has held leadership roles as partner and COO in a European patent firm and as part of Novozymes’ IP management team. He played a key role in the spin-out process of Albumedix.
Benny Buchardt Andersen
Board Member & Partner
Background: Benny is a C-suite level executive with experience in both Danish and international investments, as well as in building investment organizations.
His career includes roles as co-CEO and CIO at the pension fund PenSam, where he was responsible for managing approximately DKK 130 billion, and as CEO of DEAS Asset Management, an AIFMD-regulated company with around DKK 75 billion under management and operations across the Nordic countries. During Benny’s tenure as CEO, DEAS Asset Management grew from five to over 100 employees.
Erik Vinther
Partner
Background: Erik holds a master’s degree in business economics.
Erik has mover 30 years of experience in the pharmaceutical industry, spanning. the entire product lifecycle – from early-stage development projects to marketed products. At Novo Nordisk, Erik was responsible for the launch strategy and planning for Wegovy®, which became the first breaktrough for medical weight managementgenerating an annual revenue of USD 4.5 billion just two years after launch. He was also responsible for the relaunch of Levemir®, which, over several years, became the largest contributor to growth for Novo Nordisk.
Marigold Innovation ApS
Agern Allé 24
2970 Hørsholm
CVR 39788438
Revisor
Sønderup I/S
Autoriseret Revisor
CVR 31824559
Vilkår og betingelser
© Marigold Innovation 2025